|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
Pfizer and EMD Serono
Description and Objectives for Each
Presentation
Click on each title to participate
Recent Data and Guideline Updates
in the First Line Management of Metastatic Bladder Cancer: A Closer
Look at the Current Role of Maintenance Immunotherapy
Presented by Dr. Joaquim Bellmunt
Upon completion of this
activity, participants will be able to:
-
Examine the clinical burden of
metastatic bladder cancer in terms of relative survival,
mortality, drug utilization, adverse event management, and
hospitalizations
-
Analyze the most recent data on the efficacy and safety of
immune checkpoint inhibitors in the management of metastatic
bladder cancer in the first line setting
-
Discuss the latest recommendations for first-line maintenance
treatment for patients with metastatic bladder cancer
-
Interpret the impact of the evidence for maintenance
immunotherapy regimens in first-line metastatic bladder cancer
on treatment sequencing and long-term clinical care of the
patient
-
Identify patients with metastatic bladder cancer who would
potentially benefit from immunotherapies, in first line
maintenance settings or beyond
-
Compare and contrast adverse events associated with immune
checkpoint inhibitors in the management of metastatic bladder
cancer in order to maximize tolerability and adherence to
therapeutic regimens
Managed Care Considerations on the Evolving Role of Immune
Checkpoint
Inhibitors in the First Line Management Metastatic Bladder Cancer:
Strategies for Improved Decision-Making
Presented by Dr. Gary Owens
Upon completion of this
activity, participants will be able to:
-
Examine the economic burden of
metastatic bladder cancer in terms of relative survival,
mortality, drug utilization, adverse event management, and
hospitalizations
-
Compare and contrast efficacy and
safety data of immune checkpoint inhibitors in the management of
metastatic bladder cancer in the first line setting
-
Analyze the cost drivers associated
with the management of metastatic bladder cancer and the value
of evolving treatment approaches in lowering cost of care and
healthcare utilization
-
Assess managed care considerations
to facilitate optimal use of immune checkpoint inhibitors in
metastatic bladder cancer, including the first-line maintenance
setting
-
Transform therapeutic advances and
resource utilization data on emerging therapies in metastatic
bladder cancer into informed health plan decisions and formulary
discussions
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by educational grants from
Pfizer and EMD Serono
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional. |